Literature DB >> 7389059

Pharmacologic studies with radiolabeled N-trifluoroacetyladriamycin-14-valerate (AD 32). Comparison of total anthracycline fluorescence and radioactivity in mouse serum and urine.

M Israel, A M Karkowsky, W J Pegg.   

Abstract

In connection with pharmacologic studies with AD 32, isotopically-labeled drug prepared from 1-[14C]-trifluoroacetic anhydride and adriamycin-14-valerate was used to determine murine serum and urine levels of radioactivity. Other studies, performed in parallel, measured serum and urinary total fluorescence. Serum fluorescence disappeared in a biphasic pattern, with an initial rapid rate of disappearance followed by a somewhat slower phase. For the first hour, serum radioactivity levels were not significantly different than those measured by fluorescence. After this, however, serum radioactivity decayed at a much slower rate than did fluorescence. Furthermore, a large fraction of the injected radioactivity was found excreted in the urine, whereas urine accounted for only a small fraction of the fluorescence. These results suggest the formation, in part, of a hitherto unrecognized nonfluorescent metabolite, most probably N-trifluoracetyldaunosamine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7389059     DOI: 10.1007/bf00254026

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

1.  N-trifluoroacetyladriamycin-14-valerate: additional mouse antitumor and toxicity studies.

Authors:  L M Parker; M Hirst; M Israel
Journal:  Cancer Treat Rep       Date:  1978-01

2.  Distribution of daunomycin and adriamycin in mice. A comparative study.

Authors:  R Rosso; M Esposito; R Sala; L Santi
Journal:  Biomedicine       Date:  1973-07-20

3.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

4.  Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay.

Authors:  N R Bachur; C E Riggs; M R Green; J J Langone; H Van Vunakis; L Levine
Journal:  Clin Pharmacol Ther       Date:  1977-01       Impact factor: 6.875

5.  Urinary anthracycline metabolites from mice treated with adriamycin and N-trifluoroacetyladriamycin-14-valerate.

Authors:  M Israel; W J Pegg; P M Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1978-03       Impact factor: 4.030

6.  Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32.

Authors:  R H Blum; M B Garnick; M Israel; G P Panellos; I C Henderson; E Frei
Journal:  Recent Results Cancer Res       Date:  1981

7.  Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate.

Authors:  A Krishan; M Israel; E J Modest; E Frei
Journal:  Cancer Res       Date:  1976-06       Impact factor: 12.701

8.  Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog.

Authors:  R H Blum; M B Garnick; M Israel; G P Canellos; I C Henderson; E Frei
Journal:  Cancer Treat Rep       Date:  1979-05

9.  Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate.

Authors:  A Vecchi; M Cairo; A Mantovani; M Sironi; F Spreafico
Journal:  Cancer Treat Rep       Date:  1978-01

10.  Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat.

Authors:  M Israel; P M Wilkinson; W J Pegg; E Frei
Journal:  Cancer Res       Date:  1978-02       Impact factor: 12.701

View more
  2 in total

Review 1.  Valrubicin.

Authors:  S V Onrust; H M Lamb
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

2.  Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration. Evidence for tissue aglycone formation.

Authors:  M Israel; A M Karkowsky; V K Khetarpal
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.